Satellos Bioscience Inc. announced that Warren Whitehead, CPA, CMA, who has served as CFO for Satellos for two years, will now become Head of Corporate Strategy . Mr. Whitehead has more than 30 years of experience in senior financial management positions for publicly traded biotechnology and pharmaceutical companies. Previously, he served as CFO of ProMIS Neurosciences Inc., formerly Amorfix Life Sciences Ltd. Prior to ProMIS, he was CFO of ARIUS Research Inc., a TSX-listed company, where he provided financial guidance and leadership during the acquisition by Roche.

Prior to that, he was CFO of Labopharm Inc., where he completed a series of public equity financings, including a cross-border Nasdaq offering. Other leadership experience includes CFO of Resolution Pharmaceuticals Inc. and a position in finance and business development at Glaxo Canada (now GlaxoSmithKline). Mr. Whitehead currently serves as Director and Chair of the Audit Committee of Aptose Biosciences.

Mr. Whitehead is a CPA and Certified Management Accountant (CMA). These management updates were effective as of September 1, 2023.